Interleukin-7 immunotherapy

Claude Sportes, Ronald E. Gress

Research output: Chapter in Book/Report/Conference proceedingConference contribution

22 Scopus citations

Abstract

IL-7 is a member of the common γ -chain family of cytokines sharing a common γ -chain in their receptor. Beyond its long-established pivotal role in immune development, it has been more recently recognized as a critically important regulator of peripheral naïve and memory T cell homeostasis while its role in postdevelopment thymic function remains at best, poorly defined, and controversial. Its multiple immune-enhancing properties, most notably in the maintenance of T cell homeostasis, make it a very attractive candidate for immunotherapy in a wide variety of clinical situations. Following many years of rich preclinical data in murine and simian models, IL-7 is now emerging in human phase I trials as a very promising immunotherapeutic agent. Human in vivo data discussed here are derived from the phase I study initiated at the National Cancer Institute in collaboration with Cytheris, Inc., in a cohort of subjects with incurable malignancy.

Original languageEnglish (US)
Title of host publicationImmune-Mediated Diseases
Subtitle of host publicationFrom Theory to Therapy
EditorsMichael Shurin, Yuri Smolkin
Pages321-333
Number of pages13
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Publication series

NameAdvances in Experimental Medicine and Biology
Volume601
ISSN (Print)0065-2598

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Interleukin-7 immunotherapy'. Together they form a unique fingerprint.

  • Cite this

    Sportes, C., & Gress, R. E. (2007). Interleukin-7 immunotherapy. In M. Shurin, & Y. Smolkin (Eds.), Immune-Mediated Diseases: From Theory to Therapy (pp. 321-333). (Advances in Experimental Medicine and Biology; Vol. 601). https://doi.org/10.1007/978-0-387-72005-0_35